基因型鑒定市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、技術、應用、最終用途、地區和競爭格局分類，2021-2031年

全球基因型鑒定市場預計將經歷顯著成長，從 2025 年的 167.2 億美元成長到 2031 年的 278.6 億美元，複合年成長率為 8.88%。

這一市場擴張的主要驅動力是慢性遺傳疾病盛行率的上升，以及基因組分析在藥物基因體學和標靶治療開發中的關鍵作用。美國癌症協會估計，到2025年，光是美國就將新增約2,041,910例癌症病例，凸顯了疾病管理中對遺傳訊息的日益依賴，也凸顯了全球對精準腫瘤學和基因分型技術日益成長的需求。儘管市場成長強勁，但仍面臨許多挑戰，尤其是在資料隱私和安全方面。處理大量敏感的遺傳資訊需要遵守嚴格且往往地域分佈廣泛的監管標準，這顯著增加了診斷服務提供者和研究機構的營運複雜性和法律責任風險，從而阻礙了基因組數據的順暢交換，而基因組數據對於大規模調查和基因型鑒定服務的更廣泛臨床應用至關重要。

市場促進因素

基因型鑒定市場主要受兩大關鍵因素驅動：DNA定序和基因組分析成本的大幅降低，以及藥物基因體學應用的持續擴展。高通量技術的成熟度顯著降低了定序成本，使基因數據的取得更加便捷，並使實驗室能夠處理先前成本高昂的大量樣本。這種經濟效益的提升正在推動人群健康調查和商業性診斷的擴充性。例如，Illumina公司發布的2025年第一季報告顯示，千兆鹼基定序產量將年增超過30%；英國生物銀行也發布了包含50萬參與者的全面代謝體學數據。同時，精準醫療和藥物基因體學的發展正在從根本上改變治療方法的研發。製藥公司和臨床醫生擴大利用基因分型數據來預測藥物療效和毒性，並識別生物標記物，從而最佳化治療效果。這種向標靶治療的轉變很大程度上受到監管趨勢的推動。根據個人化醫療聯盟的數據，2024 年 FDA核准的新治療分子實體中有 38% 將是個人化藥物，凸顯了基因譜分析在現代藥物發現和核准過程中發揮的核心作用。

市場挑戰

資料隱私和安全是限制全球基因分型市場成長的關鍵挑戰。由於該產業依賴聚合海量高度敏感的基因圖譜資料集以進行藥物基因體學和精準醫療，因此極易受到網路威脅。遵守不同司法管轄區嚴格且往往分散的監管標準造成了嚴重的營運瓶頸，迫使資源轉向創新，並使跨境共用基因組數據（對生物標記檢驗和大規模研究至關重要）變得更加複雜。維護這些資料池固有的法律責任風險迫使相關人員限制存取權限，直接阻礙了臨床應用。美國醫院協會的一份報告強調了這種脆弱性的嚴重性，該報告預測，到2024年，醫療保健行業的網路攻擊和資料外洩將影響美國創紀錄的2.59億人，這將損害患者信任，並造成限制性的資料孤島，阻礙市場擴張所必需的順暢資訊交流。

市場趨勢

兩大關鍵趨勢正在塑造基因型鑒定市場：一是將人工智慧 (AI) 應用於基因型資料的解讀，二是其在農業生物技術和動物育種領域的應用不斷擴展。 AI 的融入解決了基因組資料集指數級成長帶來的分析瓶頸，推動市場從人工生物資訊轉向 AI 驅動的平台，從而實現複雜變異分類和臨床報告的自動化。 Tempus AI Inc. 發布的 2024 年第三季報告充分體現了對計算效率的需求，其 AI 數據平台收入同比成長 64.4%，達到 6450 萬美元，凸顯了行業對智慧演算法的日益依賴，以獲得可操作的精準醫療洞察。同時，基因型鑒定在農業生物技術和畜牧業領域的應用範圍已超越人類醫學，利用基因組選擇工具來提高糧食安全和畜牧生產力。農業相關企業正在廣泛採用這些工具來識別抗病性和飼料轉換率等理想性狀，最佳化育種方案，並降低營運風險。 Neogen公司2024年年度報告也反映了這種韌性，報告指出其基因組學服務收入增加了8%。這凸顯了基因型鑒定在農業供應鏈現代化和確保永續生產標準方面發揮的關鍵作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球基因型鑒定市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類別（儀器、試劑/試劑盒、軟體、服務）
  • 透過技術（PCR、毛細管電泳、微陣列、定序、質譜等）
  • 依應用領域（藥物基因體學、診斷與個人化醫療、農業生物技術、動物遺傳學等）
  • 按最終用途（製藥和生物製藥公司、診斷和研究實驗室、學術機構、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲基因型鑒定市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球基因型鑒定市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN NV
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• General Electric Compnay
• Bio-Rad Laboratories Inc.
• Standard BioTools Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Genotyping Market is projected for substantial growth, expanding from USD 16.72 Billion in 2025 to USD 27.86 Billion by 2031, at an 8.88% CAGR. This market expansion is primarily driven by the increasing prevalence of chronic genetic diseases and the crucial role of genomic analysis in both pharmacogenomics and the development of targeted therapies. The growing reliance on genetic insights for disease management is evidenced by projections such as the American Cancer Society's estimate of approximately 2,041,910 new cancer cases in the United States alone in 2025, highlighting a critical global demand for precision oncology and genetic profiling technologies. Despite this strong growth, the market faces significant challenges, particularly concerning data privacy and security. The necessity to adhere to stringent and often varied regional regulatory standards for handling vast amounts of sensitive genetic information creates considerable operational complexities and liability risks for diagnostic providers and research institutions, thereby impeding the seamless exchange of genomic data vital for large-scale research and broader clinical implementation of genotyping services.

Market Driver

The genotyping market is primarily propelled by two key factors: significant cost reductions in DNA sequencing and genomic analysis, and the expanding applications of precision medicine and pharmacogenomics. Substantial decreases in sequencing costs, driven by maturing high-throughput technologies, have democratized access to genetic data, enabling laboratories to process vast sample volumes that were previously cost-prohibitive. This economic shift fuels the scalability of population-health studies and commercial diagnostics, as demonstrated by Illumina's Q1 2025 report showing over 30 percent year-over-year increase in sequencing gigabase output and UK Biobank's release of comprehensive metabolomics data for 500,000 participants. Concurrently, the growth of precision medicine and pharmacogenomics is fundamentally reshaping therapeutic development; pharmaceutical companies and clinicians increasingly use genotypic data to identify biomarkers, predicting drug efficacy and toxicity to optimize treatment outcomes. This transition to targeted regimens is heavily supported by regulatory trends, with the Personalized Medicine Coalition reporting that 38 percent of new FDA-approved therapeutic molecular entities in 2024 were personalized medicines, underscoring the central role of genetic profiling in modern drug discovery and approval.

Market Challenge

Data privacy and security represent a critical challenge significantly hindering the Global Genotyping Market's growth. The industry's reliance on aggregating massive datasets of sensitive genetic profiles for pharmacogenomics and precision medicine makes it highly vulnerable to cyber threats. The imperative to comply with rigorous and often fragmented regulatory standards across various jurisdictions creates substantial operational bottlenecks, diverting resources from innovation and complicating the cross-border sharing of genomic data essential for biomarker validation and large-scale research. The inherent liability risks associated with maintaining these data pools prompt stakeholders to restrict access, directly stalling clinical implementation. The severity of this vulnerability is illustrated by the American Hospital Association's report that cyberattacks and data breaches within the healthcare sector impacted a record 259 million individuals in the United States in 2024, leading to eroded patient trust and the establishment of restrictive data silos that impede seamless information exchange vital for market expansion.

Market Trends

Two pivotal trends are shaping the genotyping market: the integration of Artificial Intelligence (AI) for genotypic data interpretation and the increasing application in agricultural biotechnology and animal breeding. AI integration is addressing analytical bottlenecks caused by exponential genomic dataset growth, with the market shifting towards AI-driven platforms that automate complex variant classification and clinical reporting, moving beyond manual bioinformatics. This demand for computational efficiency is evident in Tempus AI Inc.'s Q3 2024 report, showing a 64.4 percent year-over-year acceleration in its AI-enabled data platform's revenue to $64.5 million, highlighting the industry's growing reliance on intelligent algorithms for actionable precision medicine insights. Simultaneously, genotyping's expanded application in agricultural biotechnology and animal breeding broadens its scope beyond human healthcare, utilizing genomic selection tools to enhance food security and livestock productivity. Agribusinesses are extensively adopting these tools to identify desirable traits like disease resistance and feed efficiency, optimizing breeding programs and reducing operational risks, a resilience demonstrated by Neogen Corporation's Annual Report 2024, which noted an 8 percent increase in its Genomics Services revenue, underscoring genotyping's critical role in modernizing agricultural supply chains and ensuring sustainable production standards.

Key Market Players

• Thermo Fisher Scientific Inc.
• Illumina Inc.
• QIAGEN N.V.
• F Hoffmann-La Roche AG
• Danaher Corporation
• Agilent Technologies, Inc.
• Eurofins Scientific Inc.
• General Electric Compnay
• Bio-Rad Laboratories Inc.
• Standard BioTools Inc.

Report Scope

In this report, the Global Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genotyping Market, By Product

• Instruments
• Reagents & Kits
• Software
• Services

Genotyping Market, By Technology

• PCR
• Capillary Electrophoresis
• Microarrays
• Sequencing
• Mass Spectrometry
• Others

Genotyping Market, By Application

• Pharmacogenomics
• Diagnostics and Personalized Medicine
• Agricultural Biotechnology
• Animal Genetics
• Others

Genotyping Market, By End Use

• Pharmaceutical and Biopharmaceutical Companies
• Diagnostics and Research Laboratories
• Academic Institutes
• Others

Genotyping Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genotyping Market.

Available Customizations:

Global Genotyping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genotyping Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Reagents & Kits, Software, Services)
  • 5.2.2. By Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, Others)
  • 5.2.3. By Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics, Others)
  • 5.2.4. By End Use (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Genotyping Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genotyping Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Canada Genotyping Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Mexico Genotyping Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Genotyping Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genotyping Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. France Genotyping Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Genotyping Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Genotyping Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Genotyping Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific Genotyping Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genotyping Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Genotyping Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. Japan Genotyping Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. South Korea Genotyping Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Genotyping Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. Middle East & Africa Genotyping Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genotyping Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. UAE Genotyping Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. South Africa Genotyping Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. South America Genotyping Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genotyping Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Colombia Genotyping Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. Argentina Genotyping Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genotyping Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Illumina Inc.
• 15.3. QIAGEN N.V.
• 15.4. F Hoffmann-La Roche AG
• 15.5. Danaher Corporation
• 15.6. Agilent Technologies, Inc.
• 15.7. Eurofins Scientific Inc.
• 15.8. General Electric Compnay
• 15.9. Bio-Rad Laboratories Inc.
• 15.10. Standard BioTools Inc.

16. Strategic Recommendations

17. About Us & Disclaimer